This study systematically evaluates the expression profile and targeting potential of CD98HC in ovarian cancer, offering a novel ADC strategy to overcome platinum resistance and antigen heterogeneity in ovarian cancer treatment.
Literature Overview
The article titled 'Potent anti-tumor activity of CD98hc-targeted antibody-drug conjugates in ovarian cancer,' published in Signal Transduction and Targeted Therapy, systematically investigates the therapeutic potential of CD98hc as a target for antibody-drug conjugates (ADCs) in ovarian cancer. Through multidimensional experiments, the study validates high expression of CD98HC in tumor tissues, antibody-mediated internalization, and the potent anti-tumor activity of the ADC in both in vitro and in vivo models. The authors further uncover that the mechanism involves G2/M phase arrest and mitotic catastrophe, highlighting its potential application in resistant patients.Background Knowledge
Ovarian cancer (OC) is one of the most lethal gynecological malignancies, with over 70% of patients diagnosed at advanced stages, making surgical resection challenging. Although initial treatment involves surgery combined with platinum-based chemotherapy, approximately 75% of patients experience recurrence and develop resistance, posing a major clinical challenge. While PARP inhibitors and anti-angiogenic agents have improved progression-free survival in some patients, single-agent immune checkpoint inhibitors show limited efficacy, primarily due to the immunosuppressive tumor microenvironment. Therefore, there is an urgent need to develop novel targeted strategies to overcome current therapeutic bottlenecks.
In recent years, antibody-drug conjugates (ADCs) have gained significant attention due to their ability to deliver potent cytotoxic drugs precisely to tumor cells. Approved ADCs such as mirvetuximab soravtansine, which targets FRα, are used for platinum-resistant ovarian cancer, but their efficacy is limited by antigen expression heterogeneity and acquired resistance. Thus, identifying targets that are broadly expressed, internalizing, and minimally expressed in normal tissues is key to ADC development. CD98hc (encoded by SLC3A2), a transmembrane glycoprotein involved in amino acid transport and integrin signaling, is highly expressed in various cancers and associated with tumor progression and therapy resistance. Although expressed in normal tissues, specific glycosylation patterns or conformations may provide a therapeutic window. Therefore, CD98HC emerges as a promising ideal ADC target, which forms the foundation of this study.
Research Methods and Experiments
The study first analyzed CD98HC expression levels in ovarian cancer patient tissue samples using Western blot and immunohistochemistry, revealing significantly higher expression in tumor tissues compared to normal tissues, with membranous expression across different histological subtypes. Flow cytometry and immunofluorescence confirmed that the anti-CD98hc antibody (anti-CD98hcECTO) specifically binds to surface CD98HC and internalizes into lysosomes, fulfilling the key criteria for an ADC target. Subsequently, researchers constructed three ADCs with different payloads: DM1, MMAF, and DXd, and evaluated their anti-proliferative activity in multiple ovarian cancer cell lines. Results showed that anti-CD98hc-MMAF exhibited the strongest cytotoxicity, with IC50 values in the picomolar range.
To validate clinical relevance, the study further tested anti-CD98hc-MMAF activity in primary cells derived from ascites of six patients, demonstrating efficacy against both chemotherapy-sensitive and resistant samples. Mechanistic studies revealed that the ADC induces G2/M phase arrest, spindle disruption, and apoptosis. In vivo, the ADC constructed with the humanized antibody IGN523 significantly suppressed tumor growth and peritoneal metastasis in xenograft and intraperitoneal dissemination models, without significant toxicity. ELISA and Western blot further confirmed ADC enrichment in tumor tissues and activation of pharmacodynamic markers.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides a novel target-drug combination strategy for ADC therapy in ovarian cancer. Compared to FRα, CD98HC has a broader expression profile, potentially benefiting a larger patient population, especially those with platinum resistance, offering significant clinical value. Its potent in vitro and in vivo activity, along with favorable safety characteristics, makes it a highly promising clinical candidate.
From a drug development perspective, this study comprehensively demonstrates the entire process from target validation, ADC construction, in vitro screening, to in vivo efficacy evaluation, setting a benchmark for future ADC development. Future studies should further explore its efficacy in PDX models, combination strategies (e.g., with PARP inhibitors or immunotherapy), and biomarker development to guide patient selection.
Conclusion
This study systematically demonstrates the feasibility and advantages of CD98HC as a novel ADC target for ovarian cancer therapy. By developing the anti-CD98hc-MMAF conjugate, the research team not only demonstrates its exceptional potency in cell lines and primary cells but also achieves effective control of tumor growth and peritoneal metastasis in vivo models. These findings address current gaps in ADC therapy regarding antigen coverage and resistance management, offering new therapeutic hope especially for platinum-resistant patients. From bench to bedside, this study injects new momentum into the precision medicine framework for ovarian cancer and advances drug development targeting CD98HC. In the future, with further optimization of humanized antibodies and initiation of clinical trials, this strategy has the potential to become an integral component of comprehensive ovarian cancer treatment, improving long-term survival outcomes.
